Lifecore Biomedical, Inc.

LFCR

US5147661046

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
4.83 ^USD	+2.77%		-1.23%	-21.97%

11/06	22NW Fund Submits Shareholder Proposals to Lifecore Biomedical	CI
20/05	22NW Fund Nominates Candidates to the Board of Lifecore Biomedical	CI

Lifecore Biomedical, Inc. Engages BDO USA, P.C. as Independent Registered Public Accounting Firm

April 01, 2024 at 02:37 am IST

Lifecore Biomedical, Inc. announced On April 29, 2024, the Audit Committee of the Board of Directors of the company approved the engagement of BDO USA, P.C. (?BDO?) as the Company?s independent registered public accounting firm, effective immediately, to perform audit services for the fiscal year ending May 26, 2024.

Latest news about Lifecore Biomedical, Inc.

22NW Fund Submits Shareholder Proposals to Lifecore Biomedical	12/06	CI
22NW Fund Nominates Candidates to the Board of Lifecore Biomedical	21/05	CI
Lifecore Biomedical, Inc. and Curation Foods, Inc. Enters into That Certain Seventh Amendment to Credit Agreement	15/05	CI
Lifecore Biomedical, Inc. Engages BDO USA, P.C. as Independent Registered Public Accounting Firm	01/05	CI
Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report	20/04	MT
Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024	01/04	CI
Lifecore Biomedical Searches for New Auditor for Fiscal Year 2024	27/03	MT
Top Midday Decliners	20/03	MT
Lifecore Biomedical Charts Standalone Path, Names Paul Josephs as New CEO Amid Board Changes	20/03	MT
Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024	20/03	CI
Lifecore Biomedical, Inc. Announces Management Changes	20/03	CI
Tranche Update on Lifecore Biomedical, Inc.'s Equity Buyback Plan announced on July 14, 2010.	20/03	CI
Lifecore Concludes Strategic Review	20/03	CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	08/01
Sector Update: Health Care Stocks Retreat Late Afternoon	06/01	MT
Sector Update: Health Care	06/01	MT
Lifecore Biomedical Shares Rise Following Expansion of Alcon Contract	06/01	MT
Alcon, Lifecore Biomedical Extend Contract Manufacturing Agreement	05/01	MT
Lifecore Biomedical Remains Actively Engaged in its Evaluation of Potential Strategic Alternatives	05/01	CI
Lifecore Biomedical, Inc. Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements	05/01	CI
North American Morning Briefing : Geopolitical -2-	18/23/18	DJ
Lifecore Biomedical Enters Into Co-Marketing Partnership With SHL Medical	17/23/17	MT
SHL Medical and Lifecore Biomedical Enter Co-Marketing Partnership Agreement	17/23/17	CI
North American Morning Briefing : Stock Futures -2-	11/23/11	DJ
Lifecore Biomedical Releases Update on Timing of Delayed Filings, Development Portfolio	11/23/11	MT

Chart Lifecore Biomedical, Inc.

Duration

Period

More charts

Company Profile

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lifecore Biomedical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.83 USD

Average target price

6 USD

Spread / Average Target

+24.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIFECORE BIOMEDICAL, INC.	-21.97%	148M
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+44.25%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+18.45%	246B
ROCHE HOLDING AG	+2.09%	225B
NOVARTIS AG	+13.03%	218B
AMGEN INC.	+8.61%	168B

Other Pharmaceuticals